nelfinavir has been researched along with s 8932 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 6 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, KS; Cabeza de Vaca, I; Deshmukh, M; Ghahremanpour, MM; Ippolito, JA; Jorgensen, WL; Liosi, ME; Tirado-Rives, J; Zhang, CH | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Barlow, A; Barlow, B; Claassen, CW; Heavner, JJ; Heavner, MS; Landolf, KM; Yeung, SYA | 1 |
| Hussain, W; Kousar, K; Majeed, A; Rasool, N; Yasmin, F | 1 |
| Baksi, S; Bojkova, D; Ciesek, S; Cinatl, J; Claussen, C; Das, S; DeLong, LN; Domingo-Fernández, D; Ebeling, C; Eils, R; Fröhlich, H; Gadiya, Y; Gardner, S; Geisslinger, G; Gribbon, P; Hoeng, J; Hofmann-Apitius, M; Jacobs, M; Karki, R; Kodamullil, AT; Lage-Rupprecht, V; Lentzen, M; Lukassen, S; Peitsch, M; Raschka, T; Ravindra, NG; Reinshagen, J; Schultz, B; Strivens, M; van Dijk, D; Zaliani, A | 1 |
| Bartolini, D; Cruciani, G; Galli, F; Gioiello, A; Pistilli, A; Rende, M; Stabile, AM; Vacca, C | 1 |
1 review(s) available for nelfinavir and s 8932
| Article | Year |
|---|---|
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunomodulation; Interferon-alpha; Lopinavir; Nelfinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; Ribavirin; Ritonavir; SARS-CoV-2; Sulfonamides; Thiazoles | 2020 |
5 other study(ies) available for nelfinavir and s 8932
| Article | Year |
|---|---|
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
Topics: | 2020 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Phytochemicals from Selective Plants Have Promising Potential against SARS-CoV-2: Investigation and Corroboration through Molecular Docking, MD Simulations, and Quantum Computations.
Topics: Adenosine Monophosphate; Alanine; Antimetabolites; Antiviral Agents; China; COVID-19; COVID-19 Drug Treatment; Dioxolanes; Fluoroquinolones; Humans; Methyltransferases; Molecular Docking Simulation; Nelfinavir; Phytochemicals; Piperazines; Protein Conformation; RNA Helicases; SARS-CoV-2; Topoisomerase II Inhibitors; Viral Nonstructural Proteins | 2020 |
A method for the rational selection of drug repurposing candidates from multimodal knowledge harmonization.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Combined Modality Therapy; Computational Biology; COVID-19 Drug Treatment; Drug Repositioning; Drug Synergism; Drug Therapy, Combination; GTP Phosphohydrolases; Humans; Knowledge Bases; Nelfinavir; Pandemics; Raloxifene Hydrochloride; SARS-CoV-2 | 2021 |
Endoplasmic reticulum stress and NF-kB activation in SARS-CoV-2 infected cells and their response to antiviral therapy.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Caspase 9; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Cytopathogenic Effect, Viral; Endoplasmic Reticulum Stress; Humans; MAP Kinase Signaling System; Models, Biological; Nelfinavir; NF-kappa B; SARS-CoV-2; Unfolded Protein Response; Vero Cells | 2022 |